Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

HCV patients with hepatocellular carcinoma history could re-develop illness during or after taking DAAs

New research shows type 2 diabetes as important risk factor for chronic liver disease

New research shows type 2 diabetes as important risk factor for chronic liver disease

Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Mount Sinai Hospital uses M1 LUMI Bead loaded with doxorubicin for liver cancer treatment

Mount Sinai Hospital uses M1 LUMI Bead loaded with doxorubicin for liver cancer treatment

Researchers exploring ways to prevent radiation-induced cancer risk in astronauts

Researchers exploring ways to prevent radiation-induced cancer risk in astronauts

Dietary broccoli may protect against liver cancer

Dietary broccoli may protect against liver cancer

NK cells produce VEGF-A that promotes tumor growth

NK cells produce VEGF-A that promotes tumor growth

UC San Diego School of Medicine launches new NAFLD Research Center

UC San Diego School of Medicine launches new NAFLD Research Center

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

Experimental nanoparticle therapy shows promise for fighting primary liver cancer

World Hepatitis Alliance calls for comprehensive hepatitis strategies to help prevent liver cancer deaths

World Hepatitis Alliance calls for comprehensive hepatitis strategies to help prevent liver cancer deaths

Potential treatment target identified for fatty liver disease

Potential treatment target identified for fatty liver disease

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Study outlines new model to help predict age-related response to hepatitis B vaccine

Study outlines new model to help predict age-related response to hepatitis B vaccine

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

New report reveals striking variation in cancer burden within AANHPI population

New report reveals striking variation in cancer burden within AANHPI population

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Cancer mortality continues to drop in the U.S.

Cancer mortality continues to drop in the U.S.

Eliminating the 'bad seeds' of liver cancer

Eliminating the 'bad seeds' of liver cancer

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.